Drugs in MeSH Category Psychotropic Drugs

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Ascent Pharms Inc	DRONABINOL	dronabinol	CAPSULE;ORAL	207421-003	Feb 7, 2020	AB	RX	No	No
Insys Therap	DRONABINOL	dronabinol	CAPSULE;ORAL	078501-001	Aug 19, 2011		DISCN	No	No
Ascent Pharms Inc	DRONABINOL	dronabinol	CAPSULE;ORAL	207421-002	Feb 7, 2020	AB	RX	No	No
Insys Therap	DRONABINOL	dronabinol	CAPSULE;ORAL	078501-002	Aug 19, 2011		DISCN	No	No
Lannett Co Inc	DRONABINOL	dronabinol	CAPSULE;ORAL	201463-001	May 18, 2018		DISCN	No	No
Wellhouse Pharma	SYNDROS	dronabinol	SOLUTION;ORAL	205525-001	Mar 23, 2017		DISCN	Yes	No	11,253,472		Y	Y
Svc Pharma	DRONABINOL	dronabinol	CAPSULE;ORAL	078292-001	Jun 27, 2008		DISCN	No	No

Market Dynamics and Patent Landscape for Drugs in NLM MeSH Class: Psychotropic Drugs

Last updated: April 23, 2026

What is the investable scope of “Psychotropic Drugs” in MeSH?

The NLM MeSH descriptor Psychotropic Drugs is a broad pharmacologic class covering medicines that act on the central nervous system (CNS) to alter mood, perception, behavior, and cognition. For market and patent analysis, the operational scope is best treated as a basket of therapy areas where the dominant commercial products cluster:

• Antipsychotics (e.g., schizophrenia, bipolar disorder)
• Antidepressants (major depressive disorder and related indications)
• Anxiolytics and sedatives (anxiety disorders, insomnia, agitation adjuncts)
• Mood stabilizers (bipolar disorder)
• ADHD / stimulants and non-stimulants
• Antiepileptics used in psychiatric indications (where branded market presence is material)
• Antidementia and cognitive agents (where marketed for neuropsychiatric symptoms)
• Substance-use related psychopharmacology (where branded products fall under CNS categories)

From a patent-landscape perspective, “Psychotropic Drugs” behaves like a mature, label-expansion driven market with periodic renewal cycles tied to:

• New molecular entities (NMEs) that bring primary patents
• Reformulations (extended-release, depot, prodrug)
• New delivery systems (oral/implant/patch/injectable)
• Crystal forms and polymorphs
• Line extensions via new indications, dosing regimens, and controlled-release patents

How do market dynamics shape pricing, volume, and lifecycle risk?

Demand drivers and payer pressure

Psychotropic drug demand is driven by high prevalence conditions (depression, schizophrenia, bipolar disorder, anxiety disorders, ADHD) and long treatment durations. Yet the patent landscape is shaped by payer pressure and generic penetration because many core molecules have long histories and early patent estates have largely expired in most markets.

Typical market dynamics across the basket:

• High generic substitution in off-patent generics, especially for older antidepressants and anxiolytics
• Concentrated premium spend in newer branded agents with sustained differentiators (tolerability, adherence, dosing convenience, or efficacy)
• Utilization management (step therapy, formulary tiers) after payer renewals, reducing net price vs list price for incumbents

Competitive structure: brand-to-generic transition and “me-too” saturation

In psychotropic categories, clinical differentiation often exists but payer access can dominate outcomes once generics enter. That creates a repeatable lifecycle pattern:

• Branded launch captures price and volume while exclusivity is active
• Generics accelerate share loss after expiry
• The remaining brand retains a smaller loyal base via tolerability, patient adherence, or formulary positioning
• Manufacturers pursue reformulation and label-expansion to extend revenue streams

Adherence and formulation are the dominant commercial levers

Across antipsychotics, stimulants, and some antidepressants, adherence and exposure smoothing have a measurable commercial effect. This is reflected in patent activity around:

• Extended-release oral formulations
• Long-acting injectable (LAI) antipsychotics
• Once-daily dosing optimization
• Depot delivery patents (including device and dosing regimens)

Regulatory exclusivity and patent expiry determine the “cliff” calendar

For psychotropic drugs, commercial cliff risk is frequently driven by multiple overlapping IP layers:

• Primary composition of matter patents
• Method-of-use patents tied to label indications
• Formulation and delivery patents
• Pediatric exclusivity, data exclusivity, and regulatory market protection (market-specific)

In the US, FDA exclusivity and patent term adjustments influence the timing of generic entry. Patent litigation and “paragraph IV” challenges can shift effective market exclusivity further.

What does the patent landscape look like across core psychotropic categories?

The patent landscape in psychotropics is typically dense in the US and Europe, with:

• Multiple families per brand (composition, formulations, and uses)
• Continuations and divisionals that can sustain patent thickets late into life
• Long-term activity in line extensions, especially for adherence and safety improvements

Category-by-category patterns (high-level)

Antipsychotics

• Dense thickets around LAIs, dosing regimens, and formulations
• Ongoing method-of-use expansion (negative symptoms, bipolar indications, maintenance)

Antidepressants

• Moderate thicket depth for core molecules
• Reformulations and new indications (or specific subpopulations) are common

Anxiolytics and sedatives

• For older benzodiazepines: much of the value is off-patent
• For newer agents: IP often pivots to formulation and controlled-release

Mood stabilizers

• Patents frequently involve new forms, combinations, and dosing regimens

ADHD

• Stimulant and non-stimulant markets show periodic waves of reformulations and new delivery technologies
• Patent activity often emphasizes PK/PD and controlled-release schedules

What “claims that matter” usually target

In practical terms, enforceable claim scope for psychotropics typically aims at:

• Specific dosage units and schedules
• Specific release profiles and manufacturing methods
• Specific active metabolite or salt/prodrug embodiments
• Specific patient populations, endpoints, or diagnostic criteria tied to label use

This directly impacts generic and biosimilar-style design-around strategies.

Which patent and regulatory sources define exclusivity risk in psychotropics?

A complete psychotropic patent risk view requires integrating:

1. MeSH scope for therapy area identification (classification boundary)
2. US FDA Orange Book for active ingredients, patents, and exclusivity
3. Global patent data for family breadth and earliest priority dates
4. Court and litigation records where relevant for expiry-driven calendar shifts

For the US, the FDA Orange Book is the primary operational dataset for patent expiry and exclusivity status, listing:

• Applicant/holder
• Active ingredients
• Dosage forms
• Patents covering the drug product and the methods of use
• Exclusivity codes and related information

The Orange Book is maintained by FDA and is the standard reference for generic entry planning. [1]

How does patent expiration propagate into market share loss?

Psychotropics show a repeatable dynamic:

• Primary patents drive earliest generic entry dates for the specific embodiment
• Formulation and method-of-use patents can delay generic entry for some products via patent list coverage or litigation
• Exclusivity can extend market protection even after patent expiry, depending on the exclusivity type and the regulatory pathway

The outcome is a multi-stage erosion curve:

• Initial share loss at the first legal barrier fall
• Continued losses as next barriers fall across dosage forms and lines
• Residual premium retention for patients requiring tolerability profiles or adherence advantages

For investors and R&D leaders, the critical variable is not just the last patent expiry, but whether the relevant commercial product maps to multiple Orange Book-listed patents and whether those patents are actively defended.

Patent landscape mechanics: what to model for a psychotropic basket

For decision-grade analytics, the landscape is typically modeled using a few parameters:

• Index product mapping: map branded competitors per indication within the MeSH basket
• Earliest priority and last expiry: establish family timeline and practical expiry windows
• Patent claim type distribution: composition vs formulation vs method-of-use
• Patent term and exclusivity overlap: identify whether exclusivity covers gaps after patent expiry
• Dosage-form granularity: LAIs and ER products often have distinct patent sets

In psychotropics, dosage-form granularity is critical because generics often launch first on one form or one strength, leaving other forms protected or constrained by product-specific patents.

What does the MeSH-based classification imply for dataset construction?

MeSH is a controlled vocabulary designed for indexing. “Psychotropic Drugs” is a descriptor, not a single chemical entity. That means:

• A MeSH-basket analysis aggregates many unrelated pharmacologic classes under one label
• Patent timelines vary widely by molecule generation and launch era
• Average expiry dates are misleading without weighting by revenue and present product mix

For investment screening, the correct approach is to treat MeSH as the candidate pool definition, then weight by:

• Active marketed products per region
• Sales share within each category
• Patent protection strength for each product form

Key business implications for R&D and investment

R&D positioning

R&D programs in psychotropics tend to focus on:

• Differentiated delivery to extend lifecycle beyond composition
• Repositioning and label expansion to create method-of-use patent leverage
• Safety/tolerability improvements that can support switching and new prescribing patterns

Because generic substitution is rapid for many mature molecules, the practical advantage often comes from barriers that are harder to replicate:

• LAI manufacturing and dosing protocols
• Specific release kinetics and formulation approaches
• Patented titration schedules and administration methods

Investment diligence focus

For a psychotropic opportunity, the diligence target is whether the commercial moat is:

• Composition-dependent (primary IP)
• Embodiment-dependent (formulation, device, delivery)
• Use-dependent (method-of-use and label constraints)
• Regulatory-exclusivity-dependent (exclusivity shields or slows entry)

Orange Book coverage often reveals whether a product’s legal exposure is broad (many listed patents) or narrow (few listed patents). [1]

Key Takeaways

• “Psychotropic Drugs” (MeSH) is a basket descriptor spanning multiple CNS therapy areas, so patent risk and expiry calendars differ widely across products.
• Market dynamics in psychotropics are driven by payer pressure and rapid generic substitution, making formulation and delivery differentiation commercially important.
• Patent landscapes are typically thickest where delivery systems and dosing regimens matter most (notably LAIs and controlled-release products).
• For US market exclusivity and entry planning, the FDA Orange Book is the operational backbone for mapping listed patents, dosage forms, and exclusivity. [1]

FAQs

1) What is the fastest way to identify patent expiry risk for US psychotropic brands?

Use the FDA Orange Book to identify all listed patents and exclusivity relevant to each active ingredient and dosage form, then build a dosage-form-specific expiry calendar. [1]

2) Why do psychotropic patent thickets often persist even after composition patents expire?

Because reformulation, delivery, and method-of-use patents can remain listed and enforced against generic embodiments, especially for extended-release and LAI products. [1]

3) Does MeSH classification determine the legal patent landscape?

No. MeSH defines indexing scope. Patent landscape strength is molecule- and product-form specific and should be assembled product-by-product rather than using MeSH as a proxy for protection duration.

4) What claim types most commonly sustain exclusivity in psychotropics?

Formulation and delivery claims (including controlled-release/LAI embodiments) and method-of-use claims tied to labeled dosing and indications tend to sustain enforceable barriers late into the lifecycle.

5) What market factor most affects the effective impact of patent expiry in psychotropics?

Formulary access and adherence-linked differentiation determine how quickly prescribers and patients switch after first legal barrier loss.

---

References

[1] U.S. Food and Drug Administration. (n.d.). Drugs@FDA: FDA Orange Book (Approved Drug Products with Therapeutic Equivalence Evaluations). FDA. https://www.accessdata.fda.gov/scripts/cder/ob/